High-dose treatment with ADXS11-001, a listeria monocytogenes (Lm)-listeriolysin O (LLO) immunotherapy, in women with cervical cancer

Podobne zapisy

• Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy
  od: Mkrtichyan, Mikayel, i wsp.
  Wydane: (2013)
• A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes–Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer
  od: Basu, Partha, i wsp.
  Wydane: (2018)
• Listeria monocytogenes (Lm)-LLO immunotherapies reduce the immunosuppressive activity of myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment
  od: Wallecha, Anu, i wsp.
  Wydane: (2013)
• Systemic listeriosis following vaccination with the attenuated Listeria monocytogenes therapeutic vaccine, ADXS11-001
  od: Sacco, Joseph J., i wsp.
  Wydane: (2015)
• Lm-LLO-Based Immunotherapies and HPV-Associated Disease
  od: Anu Wallecha, i wsp.
  Wydane: (2012-01-01)